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 An anti-inflammatory system was created to reduce the inflammation and fibrotic scarring caused by a subcutaneous biosensor. This system 
was comprised of Titania nanotubes, chitosan hydrogel, and drug-releasing nanoparticles, and was aimed at reducing the adhesion and activation 
of macrophages. Testing suggests that the system reduces macrophage activity, and therefore the subsequent fibrotic encapsulation, in 
comparison to Ti foil, TiO2 nanotubes, and chitosan hydrogel acting in isolation. 
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Abstract 
Abstract—An anti-inflammatory system was created to reduce 
the inflammation and fibrotic scarring caused by a subcutaneous 
biosensor. This system was comprised of Titania nanotubes, 
chitosan hydrogel, and drug-releasing nanoparticles, and was 
aimed at reducing the adhesion and activation of macrophages. 
Testing suggests that the system reduces macrophage activity, 
and therefore the subsequent fibrotic encapsulation, in 
comparison to Ti foil, TiO2 nanotubes, and chitosan hydrogel 
acting in isolation. 
INTRODUCTION 
The inflammatory response of the human body to the 
internal presence of foreign materials promotes the continued 
health and well-being of an individual. Unfortunately, in 
regards to subcutaneously implanted biosensors, this immune 
response disrupts the performance of the device’s sensing 
capabilities by generating fibrotic tissue between the sensor 
and the body, as seen below in Fig. 1 [1][2]. The formation of 
this tissue matrix prevents the diffusion of metabolites to and 
from the sensor, resulting in a loss of metabolite sensitivity 
and eventual device failure [3]. 
In order to extend sensor functionality, the generation of 
fibrotic scarring must be delayed. Macrophages have been 
identified as a potential target to accomplishing this aim; they 
are the primary phagocytotic cell of the acute inflammatory 
response, and release pro-inflammatory cytokines to attract 
additional macrophages to the site upon activation [4][5].  
This macrophage activation has been demonstrated to be 
reduced when exposed to TiO2 nanotubes with a diameter of 
70 nm as opposed to other metals or untreated titanium [6]. As 
Ti is considered to have superior biocompatibility, the 
enhanced biocompatibility of TiO2 nanotubes suggests 
potential as an anti-inflammatory material when used in 
conjunction with other approaches such as anti-inflammatory 
drugs and hydrogels.    
Therefore, the primary objective of this project is to 
investigate the viability of a TiO2 nanotube anti-inflammatory 
system for a subcutaneous biosensor to (1) reduce macrophage 
activation at the site of biosensor insertion, (2) delay the 
inflammation response and fibrotic scarring development, and 
(3) extend the functional lifetime of that biosensor. To that 
aim, TiO2 nanotubes were combined with a 1% chitosan 
solution and PLGA nanoparticle drug-delivery system and 
assessed on their combined ability to reduce the inflammatory 
response.  
 
 
 
 
 
 
 
Fig. 1: Common inflammatory response impediments to biosensor 
functionality [1]  
METHODS 
Titania Nanotube Formation 
Titanium foil (99% pure, 0.127mm thick) was obtained as a 
gift from Dr. Menon of Northeastern University. 3x5 cm 
pieces were ultrasonically cleaned in 100% isopropanol for 
15mins. Samples were anodized at 15V in 0.25M hydrofluoric 
acid for 45mins and subsequently annealed in a tube furnace at 
400°C for 4 hours. After annealing, Ti samples were rinsed 
with DI water, pure isopropanol, and ultrasonically cleaned in 
pure isopropanol for 15mins. Ti samples were cut into 0.5x0.5 
cm squares and ultrasonically cleaned in pure ethanol before 
testing. Samples were characterized by SEM.  
 
1% Chitosan Gel Production and Application 
Chitosan was dissolved in 2% acetic acid solution with 
magnetic stirring for 2 hours. Chitosan coated samples were 
dipped in the solution prior to seeding and refrigerated at 4°C 
for 24 hours, and then placed in a 37°C oven until testing.  
 
Macrophage Adhesion and Activation 
Immortalized macrophages, harvested from C57bl/6 mice 
treated with J2 virus, and primary macrophages from C57 
Black /6J (C57BL/6J) mice were a gift from UMASS Medical 
School. The macrophages were seeded onto a 48-well plate 
containing: 1% chitosan hydrogel, Ti foil, TiO2 nanotubes, 
chitosan-coated Ti foil, chitosan-coated TiO2 nanotubes, and a 
polystyrene control. Macrophages were tested for adherence, 
activation, and viability 1 and 7 days after seeding. 3 samples 
from each parameter were treated with 2.5% Phalloidin and 
0.1% Hoechst stains to determine adhered population and 
viability. This analysis was conducted using an upright 
fluorescence microscope. The remaining samples were 
analyzed using SEM to observe adherence and activation. 
 
Nanoparticle Release 
Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were 
created following a procedure by Chenna et al. and loaded with 
12.5 μg/mL of Fluorescein isothiocyanate (FITC) [7]. 5 mg of 
the particles were mixed with 1.2% agarose and deposited into 
glass vials, three samples with 100 μL and three samples with 
150μL, and left at 4°C for 1 hour. 10% PBS was added to the 
vials, 250μL and 300μL respectively, after gelation. PBS was 
collected after 1, 2, and 3 days, and then every alternate day 
until day 13. Equal amounts of PBS were collected and 
replaced. The collected PBS was analyzed using a Nanodrop 
2000 Spectrophotometer to test the FITC absorbance. 
 
RESULTS 
Analysis of Nanotube Dimensions 
Anodization produced TiO2 nanotubes with an average 
outer diameter of 70 nm and an average inner diameter of 40 
nm. The average length of the nanotubes was 200 nm measured 
vi 
 
from the surface of the foil. The tubes covered the entirety of 
the foil surface. 
 
Macrophage Viability 
Chitosan-coated TiO2 nanotubes seeded with primary 
macrophages noticeably demonstrated the lowest level of cells 
during fluorescence testing in comparison to all other samples 
at both time points, especially compared to the Ti foil and 
control. Wells seeded with immortalized macrophages were 
difficult to analyze due to cell proliferation. 
 
Macrophage Adhesion and Activation 
All samples demonstrated an amount of macrophage 
adhesion and activation, which was determined by cell 
morphology as shown in Fig. 2. Ti foil possessed the highest 
amount of adhesion and activation among the 1 day samples; 
chitosan-coated samples possessed the least with nearly all of 
the adhered macrophages remaining inactivated. After 7 days 
the chitosan-coated samples demonstrated minimal adhesion 
and activation in comparison to the non-chitosan coated 
samples and the control. Areas where the chitosan layer had 
torn were more attractive to macrophage adhesion; this was 
observed more often on Ti foil samples than TiO2 nanotubes. 
 
 
Fig. 2: (A) Day 1 Ti foil with activated (left) and inactivated (right) 
macrophages, (B) Day1 chitosan-coated TiO2 nanotubes with an inactivated 
macrophage 
 
Nanoparticle Release Study  
The nanoparticle release study lasted 13 days. A plateau 
resulted in both well types at day 7 at a cumulative 
concentration of about 10μg/mL, as shown in Fig. 3. 
 
 
Fig. 3: The cumulative concentrations of FITC released over 13 days from 
PLGA nanoparticles in agarose 
 
DISCUSSION 
As observed in the SEM images, greater macrophage 
adhesion and activation occurs on Ti samples not coated in 
chitosan. However images of the chitosan-covered foil and 
chitosan-coated  nanotube samples suggest that the nanotubes 
promote chitosan adherence, and thus have a lower amount of 
macrophage adherence and activation due to increased 
hydrogel attachment. This hypothesis was substantiated by 
florescence imaging, which revealed a smaller macrophage 
presence on chitosan-covered TiO2 nanotubes than on any 
other sample. These initial results demonstrated that the 
chitosan-Ti anti-inflammatory system was successful in 
reducing macrophage activity. The addition of anti-
inflammatory drug loaded nanoparticles with a 7 day release 
could further reduce the macrophage activation. Therefore, this 
system may have the potential to increase the amount of time 
the biosensor can remain in vivo before fibrotic encapsulation.  
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1.0 Introduction 
The use of biomaterials in applications such as prostheses, medical devices, and biosensors for treatment 
and diagnostics has become an important part of modern medicine. However, biomaterials used for 
human applications stimulate a negative immune response when implanted into living tissue. 
(Wisniewski, 2009) Inflammation is the first and most common response from the body once the presence 
of a foreign material is detected. (Wisniewski, 2009) In most cases this inflammatory response will lead 
to the formation of fibrotic tissue. In the case of biosensors, this tissue accumulation will ultimately result 
in device failure. (Higgins, 2009) For this Major Qualifying Project (MQP) team intends to design a 
system to reduce the inflammatory response that follows biosensor implantation, and to prevent fibrotic 
tissue formation. In performing these functions the device will extend the functional lifetime of implanted 
biosensors.  
2.0 Literature Review 
In order to create an anti-inflammatory system for a subcutaneous biosensor, some topics must be 
addressed so as to fully understand the scope of the project. Therefore, the factors of the immune system, 
biosensors, and previous solutions must be discussed. A review of biosensors will first be presented. 
2.1 Biosensors and Inflammation 
Biosensors have become a commonly used medical device, necessary for patients with a variety of 
disorders, but are largely associated with diabetes. To get accurate, constant readings of metabolites, the 
sensor must be implanted into the patient; various types of biosensors will be implanted into a patient. 
These sensors are used in a wide variety of applications, from glucose monitoring to examining the 
electrical impulses being sent from the brain. Depending upon the function of the sensor dictates the 
placement of the biosensor. (Yoo, 2010) This paper will be focusing on subcutaneous metabolite 
biosensors.  
2.1.1 Biosensors 
Metabolite biosensors are able to detect a wide range of analytes, including glucose and various amino 
acids. Patients will have a biosensor implanted into their skin and have it remain in a subcutaneous region 
for about one week before it must be replaced. The sensor will give accurate and constant readings on the 
patient’s metabolite levels throughout the day, which can help in detecting fluxes and the daily patterns. 
(Vaddiraju, 2010) The sensor can either work on its own to report readings or can be synced with a drug 
delivery system for used in diabetic patients in the attempt to regulate the glucose concentrations before 
they reach critical levels. (Yoo, 2010) In order for these functions to be met, the biosensor needs to be 
sensitive to the surrounding environment, have a low response time, and be selective to the metabolites 
needing measurement so as to not generate results based upon other analytes. (Atta, 2011) 
Back in 2004, the main form of biosensor was the glucose monitor, which accounted for about 85% of the 
$5 billion biosensor market. With the rise in diabetes and increased abilities and applications of 
biosensors, this market was expected to have doubled since then, therefore having a market value of 
around $10 billion. (Yoo, 2010)  
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Depending upon the necessary function of the biosensor dictates its location. In regards to metabolic, 
subcutaneous biosensors, the sensor is typically implanted in the abdomen region under the dermal skin 
layer. Therefore, the sensor is being inserted into the body at a depth between 4 and 12 mm. Depending 
upon the shape of the sensor, it can be inserted directly into the body, which causes torsional stress upon 
the sensor. The sensor can also be surgically implanted, where an incision is made in the skin prior to 
biosensor insertion, reducing the stresses exerted on the sensor.  
In order to function properly, a biosensor needs to have the following key parts. It must have an electrode 
that can be implanted into the body, which in the third-generation glucose monitors is a needle-like 
projection. However, the electrode can also be a blunt-surfaced insert with a diameter of about 3 mm. The 
needle-like electrodes allow for a smaller puncture and easier insertion. The working and reference 
electrodes are what come into contact with the ions and metabolites in the interstitial fluid found in the 
body’s subcutaneous region. (Yoo, 2010) The electrode pair is connected to an ex vivo segment where the 
metabolite levels are read and recorded every five minutes. Fig. 1 shows the components of the 
implantable section of a subcutaneous biosensor. 
 
Figure 1: Diagram of a needle-like electrode of a subcutaneous biosensor (Wang, 2001) 
The implantable segment is coated in bioinert materials to reduce the negative responses the body is 
capable of and to keep from exposing possible toxins to the region. Though this coating does still elicit an 
inflammatory response, the sensor is still able to function continuously for three to seven days. (Wang, 
2001) However, after this time, the sensor must be removed due to the worsening inflammatory response. 
2.1.2 Inflammatory Response 
The human body’s initial inflammatory response to the implantation of a biosensor is activated by the 
ensuing injury to vascularized connective tissue. The biosensor site responds to this insertion as it does 
any other wound, in three stages. These stages in include: acute inflammation, chronic inflammation, and 
tissue granulation.   
2.1.2.1 Stage 1: Acute  
Acute inflammation is a rapid response to tissue injury that can last anywhere from minutes to days. It 
involves exudations of fluid and plasma proteins similar to edema, including emigration of leukocytes, 
neutrophils and white cells that have moved from blood vessels to the perivascular tissue at the implant 
site. Neutrophils and monocytes accumulation is an important sign of the inflammatory reaction. 
(Anderson, 2001) This accumulates through adhesion, phagocytosis, and extracellular release of 
leukocytes. Following the release of leukocytes to the implant site, phagocytosis and release of enzymes 
due to activation of neutrophils and macrophages, degradation of biomaterial could possibly occur 
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depending on its properties. Some of the visual characteristic that the host experiences are: redness, heat, 
pain, swelling, and loss of function. (ProSono, 2006) 
2.1.2.2 Stage 2: Chronic  
The continuation of acute inflammation brings the inflammatory response to its second stage: chronic 
inflammation. (ProSono, 2006) One of the main characteristics of the chronic inflammatory response is 
the presence of macrophages, monocytes, and lymphocytes, with proliferation of blood vessels and 
connective tissue. The most important cell of the chronic inflammation is the macrophage since it 
produces a great number of biological active products. Some of these products are reactive oxygen 
metabolites, coagulation factors, and growth-promoting factors. These growth factors are involved in 
various stages of the wound healing response. (Anderson, 2001)  
2.1.2.3 Stage 3: Tissue Granulation  
Tissue granulation occurs after chronic inflammation has set in around the wound site. Granulation tissue 
can be describe as a pink, soft granular appearance on the surface of healing wound, and its ability to 
proliferate new small blood vessels and fibroblast. The primary tissue issues involved in this response is 
type I collagen which it predominates and help the formation of fibrous capsule. (Anderson, 2001)  
2.1.3 Impact of Fibrotic Encapsulation 
The immune system response described above that is generated by biosensor implantation is detrimental 
to the long term functionality of the sensor. The acute inflammation described in Section 2.1.2.1 is 
initiated immediately following the in vivo insertion of the biosensor, and a host of cells begin to 
accumulate at the site. The sensor is identified as a foreign body by the immune system, and as such the 
innate reaction is to phagocytize it to be either destroyed or presented to the T cells. This method is 
ineffective against a permanent structure such as a biosensor, and as such instead of being performed and 
reaching a natural conclusion the immune system continues to generate an inflammatory response. 
Although the continuous attack of the immune system upon the biosensor is unable to remove the device 
from the body, it does have a detrimental effect on upon both its structural integrity and ability to sense 
and diffuse analytes. (Wisniewski, 2009) The primary reasons for this loss of function, and eventual 
failure, include: electrical failure, delamination of membranes, enzyme degradation, membrane 
biodegradation, electrode passivation, fibrous encapsulation, and membrane bio-fouling. Fig. 2 
depicts where on the biosensor these processes have an effect. 
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Figure 2: Schematic of Subcutaneous Biosensor Following Insertion (Wisniewski, 2009) 
Although it has not been clinically determined which of these impediments poses the greatest restriction 
on biosensor longevity, fibrous encapsulation is the final effect of the inflammatory response and is 
ultimately the occurrence which halts device functionality. (Wisniewski, 2009) At the onset of acute 
inflammation, proteins and cells adhere to the surface of the biosensor to begin the process of membrane 
bio-fouling. Over an extended duration of time this deposition of proteins builds away from the 
membrane and forms a matrix that surrounds the biosensor. This matrix will impede the capabilities of the 
biosensor by blocking the signal interaction between the biological element and transducer. Once the 
capsule has reached a thickness of 500 micrometers, signal interaction is no longer possible, and the 
biosensor is no longer functional.  
Though the biosensor was designed to be implanted in the body, long-term implantation has been a 
problem. As with all foreign implants, the body produces an immune response to counter the new 
material. In other types of implants, such as catheters, the immune response is not a big problem, but that 
is not the case with biosensors. The subsequent scar tissue capsule formation around the electrode 
impedes the ability for the metabolites to reach the biosensor. The initial impedance will lead to readings 
being different from the actual metabolite levels, but as the scar formation continues the biosensor 
eventually is unable to receive any readings. Even though the electrode is typically coated in a bio-inert 
material, the acute immune response will still be triggered. The term bio-inert refers to the fact that the 
material does not release toxins in the body or produce other negative effects. However, the formation of 
the scar tissue is what makes the material completely bio-inert as it will no longer be able to interact with 
the body whatsoever. 
2.2 Current Anti-Inflammatory Approaches 
Biosensors have a limited functionality due to the inflammatory response it elicits. In order to attempt to 
reduce this inflammation or otherwise ensure that the biosensor functions properly, there are a few 
currently used methods patients and doctors will employ. These current mitigations include frequent 
removal, addition of coatings, and drug delivery systems.  
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2.2.1 Biosensor Removal 
Currently, a biosensor is only supposed to remain in the body for 3 to 7 days before being removed, 
replaced, and relocated. This is to ensure that the biosensor is fully capable of accurate and precise 
readings of the metabolites. If the biosensor stays in longer than the recommended time, the scar tissue 
formation will impede the metabolites ability to reach the biosensor, resulting in a failure of proper 
function. Therefore, the sensor is removed from that area and moved to another location. This process is 
repeated one or two times a week though it is painful, burdening, and expensive for the patients. (Yoo, 
2010) It is because of this that there has been research looking into ways to increase the amount of time 
between sensor relocation. 
2.2.2 Coatings 
In the attempt to extend the life of the biosensor is to coat the implantable section of the electrode with a 
bio-inert material. This is typically a synthetic or a natural polymer that will not degrade or release any 
sort of toxin into the body. These materials do not produce a highly aggressive response and will not harm 
the body as it is not an excessive threat. (Oliveira, 2005) Commonly used synthetic coatings include 
Teflon, PEO, and PEG. (Yoo, 2010) Natural polymer coatings include alginate and chitin. (Wang, 2007) 
The coating must be carefully chosen and applied so as not to create an impenetrable barrier between the 
electrodes of the biosensor and the metabolites it monitors. If the coating proved to inhibit the biosensors 
function, then it is not worth the benefits of a reduced inflammatory response. 
These coatings may help to deter the immune response for a short amount of time as it is not as large of a 
threat to the body as other materials, but it will still invoke the inflammatory response needed for healing 
the site. Because of this, the coating is many times used in addition to a drug delivery system, where the 
coating can help to secure the delivery vehicles to the biosensor to prevent migration. (Vaddiraju, 2010) 
2.2.3 Drug Delivery  
Another method of prolonging biosensor functionality is the delivery of anti-inflammatory drugs into the 
areas of biosensor insertion. A common drug used for this is dexamethasone, which is quite effective in 
reducing inflammation and does not have extensive side effects when delivered locally. Many studies 
have been conducted utilizing different delivery methods for dexamethasone and other anti-inflammatory 
drugs. Injection is a delivery possibility, though it is limited as it allows for spikes in the amount of drug 
injected, but does not regulate a controlled, continuous release. In order to attain this more continuous 
release as opposed to temporary spikes, microspheres, nanotubes, and degradable coatings have been 
used. The microspheres and degradable coatings are made of degradable or porous polymers that contain 
the anti-inflammatory drug. For degradable polymers, the rate of the degradation dictates the rate at which 
the drug is released. In the porous polymers, the rate of dispersion depends upon the pore size and the 
environmental factors effect on the rate of diffusion. The polymers that make up these coatings and 
microspheres are typically PGLA, which is used for its bio-inert characteristics and well-defined 
degradation rate. (Jayant, 2007) However, for a natural microsphere, alginate is commonly used. (Wang, 
2007) Nanotubes are another form of drug delivery which utilizes diffusion to release the drugs into the 
body. The nanotubes are typically made of carbon and vary in size depending upon the duration of drug 
delivery needed. They are typically put in a bio-inert coating to keep them close to the insertion site and 
reduce the possible migration.  
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3.0 Project Strategy 
To begin the design process for this project, a client statement was composed to meet both client needs 
and the problem of inflammatory impediments to biosensor functionality. Design objectives were 
developed from that statement, as well as design constraints. Certain constraints were a result of the 
Worcester Polytechnic Institute (WPI) MQP structure, and while they were considered it was 
acknowledged that they are not unique to this problem.  
3.1 Client Statement 
Professor Anjana Jain of WPI’s Biomedical Engineering (BME) Department commissioned the team to 
design an anti-inflammatory device that could be used in conjunction with an in vivo biosensor to reduce 
initial inflammation at the site of biosensor insertion, delay development of fibrotic scarring, and 
ultimately extend the functional lifetime of that biosensor. Additional objectives included developing a 
device that is cell specific, localized in its effect, operational immediately following insertion, and is easy 
to apply to the biosensor. As it is to be used in vivo, the device must also be biocompatible.  
3.2 Objectives 
The following is a ranked list of design objectives generated from the client statement and 
correspondence with the advisor.  
 Biocompatible 
 Compatible with Biosensor Operation 
 Long Lasting 
 Localized 
 Immediate 
 Cell Specific 
 Easy to Apply 
 
The two primary objectives identified by the team are that the device be biocompatible and compatible 
with biosensor operation. The former is fairly obvious in its importance; if the anti-inflammatory device is 
not compatible with the human body then it will produce more of an immune response then the sensor 
itself and could be rejected outright. The latter, that the device be compatible with biosensor operation, is 
to ensure that whatever anti-inflammation method is utilized has neither a negative physical effect on the 
biosensor nor a negative effect on the sensor’s functionality.  These objectives were ranked to be of the 
highest priority because should they not be met it is unlikely that any successful outcome will result. 
“Long Lasting” was ranked third as an objective as the ultimate goal of the device is to extend the 
functional lifespan of the biosensor. In order to do so the device must be long lasting itself or its effect 
must be. Localized, immediate, cell specific, all refer to the effect of the anti-inflammatory device, and 
were determined to be important but not crucial to the success of the device. It is preferable that the three 
objectives be met, but the team can envision working scenarios where one or more are not. The objective 
“easy to apply” was ranked the lowest of all seven. It refers to the ability of the user to apply the device to 
either the patient or the biosensor, an ability that would have an effect during testing and on marketability  
3.3 Constraints 
Below is a list of design constraints exclusive to this MQP: 
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 All materials must be biocompatible  
 Lack of human immune system on which to test 
 System must not impede biosensor function 
 System must not permanently affect the immune system 
Additional constraints ubiquitous to all BME MQP projects: 
 Budget 
 Development and testing time 
 Limits on material selection and availability  
 Follows regulatory requirements and is safe for user and patient 
The initial four constraints listed are specific to this MQP and its device. Firstly, as the device must be 
biocompatible, as previously stated in section 3.1, there are severe limitations on what materials are 
available to use in the design. Anything that is toxic or produces a negative response in the body must be 
immediately disregarded. Secondly, although the team is designing a device to be used in the human 
body, there is no possibility that it could be tested in human patients. Therefore a model of the human 
immune system must be developed for testing, the limitations of which for a constraint on the design and 
testing process. That the system must not impede biosensor function is similar to the objective on 
biosensor compatibility and, like the biocompatibility constrain, imposes restrictions on the material, 
shape, and size of the device. Finally, the last constraint is that the system must not permanently affect the 
immune system. This constrain is not limited to a permanent negative effect, as a permanent neutral effect 
would be just as unwanted in a human subject. 
The additional four constraints, listed separately, refer to limitations that all MQPs at WPI are bound by. 
There is a finite amount of money that is dedicated to the project, as well a definite duration of time. 
Materials are limited based on monetary reasons, and on the team and advisor’s ability to obtain them. All 
projects and devices must be safe for the user and patients that they are intended for, and must comply 
with all federal and state regulations pertaining to their use. 
4.0 Design Selection 
Final design selection was made by gathering the information obtained from the literature review and 
analyzing how each potential option would meet the previously determined client statement, objectives, 
and constraints. The selection of final design components, how they are expected to work in conjunction 
with one another, and the rationale behind their selection is found below.  
4.1 Macrophages 
Macrophages are differentiated monocytes that participate in the innate immune system. They were 
selected as a design component as they are the primary phagocytic cells in inflammatory response, and 
immigrate to the site of injury from the surrounding blood vessels. Once present macrophages either 
engulf cellular debris and foreign bodies, or stimulate the action of lymphocytes, an immune cell involved 
in the second stage of the inflammatory response. (Leibovich, 1975) Therefore, by reducing macrophage 
activity around a biosensor it is possible to reduce the entire inflammatory response and thus delay the 
occurrence of fibrotic scarring. 
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4.1.1 Stage of Inflammation 
Within hours after injury has occurred to the vascularized connective tissue macrophages begin to 
proliferate at the site. (Leibovich, 1975) At this stage local proteins have already begun to opsonize the 
identified foreign bodies, which allows for macrophages to adhere to and phagocytize these particles 
more easily. Macrophages will continue to diffuse into the wound site via diapedesis from nearby blood 
vessels throughout the entirety of the acute stage of inflammation, and will reach maximal concentration 
levels at roughly the third day following injury. (Leibovich, 1975) Although macrophages will reach peak 
numbers at this stage, they remain at the site for up to 16 days and thus carry into the second stage of 
inflammation. (Butterfield, 2006) 
4.1.2 Location of Macrophages 
Macrophages are present in small quantities in almost every tissue at all times. (Sorg, 1991) Once 
activated by tissue injury cells migrate en masse and adhere to the location site by diffusing through the 
blood vessels. In addition to performing phagocytosis, adhered and activated macrophages secrete pro-
inflammatory cytokines that encourage the proliferation of additional macrophages to the location. 
(Butterfield, 2006) This generates a positive-feedback response that ensures the constant presence of the 
cells for as long as the inflammation process lasts. 
4.1.3 Impact of Macrophages on Biosensor Implantation 
Macrophages limit biosensor longevity by exacerbating the inflammation response caused by device 
insertion. The positive-feedback loop referenced in the previous section maintains a continuous immune 
response until the foreign particles are able to be phagocytized and removed which, in the case of 
biosensors, is impossible. As a result, activated macrophages continue to secrete inflammation-inducing 
cytokines that progress the inflammatory response from the acute stage to tissue granulation. Macrophage 
interactions with proteins can also prove to be detrimental to biosensor functionality. Proteins begin to 
coat the sensor surface immediately following implantation, which attracts macrophages. (Leibovich, 
1975) As macrophages are unable to phagocytize the surface they gradually accumulate, and eventually 
form the inner layer of fibrotic scarring. Because of the primary role that macrophages play in the acute 
inflammatory response, and thus the ensuing fibrotic scarring, they were selected as the principal target of 
the anti-inflammatory system. Effectiveness of this system could then be determined by observing 
macrophage activity; specifically, the adhesion and activation of the macrophages to the foreign surface 
would indicate its biocompatibility and the level of the acute inflammatory response. 
4.2 Titania Nanotubes 
The high biocompatibility, among other favorable mechanical properties, of Titanium (Ti) has increased 
its viability in medical instruments and implants. As a result Ti and Ti-based alloys are commonly utilized 
in devices ranging from dental implants to fracture fixations, where strength, corrosion-resistance, and 
bioadhesion are necessary. (Doong, 2010) Titania (TiO2) nanotubes, or anodized Ti foil, have been found 
to demonstrate increased levels of this inherent biocompatibility, for reasons which are yet unknown, 
particularly when in contact with macrophages. As described in Section 4.1, when introduced to a foreign 
material macrophages adhere to its surface and subsequently activate, recruiting more cells.  However, 
interactions with TiO2 nanotubes have shown a decrease in macrophage surface adhesion, as well as a 
reduction in the number of activated macrophages, when compared to a Ti foil control. (Chamberlain, 
2011) (Rajyalakshmi, 2011) As a result of these studies, particularly the fact that the primary component 
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of the inflammatory response-macrophages-are affected, TiO2 nanotubes were selected as a primary 
component and structural basis of the anti-inflammatory system design.  
4.3 1% Chitosan Gel 
Hydrogels have proven useful in a vast number of medical applications, being used as regeneration 
scaffolding, drug-delivery vehicles, and biocompatible coatings. It is the latter function that is of greatest 
interest in this design selection, as a hydrogel would have the ability to coat the TiO2 foundation of the 
system and, ideally, increase its biocompatibility. The primary division between hydrogel types, and the 
determining factor in their medical application, is whether they are found naturally or are synthetically 
created. Synthetic hydrogels allow for consistency in results as they have been engineered to meet certain 
mechanical criterion. These synthetic hydrogels can be altered to remain for a long period of time in the 
body, have varied strength and elasticity, and even be altered in vivo depending upon the environment. In 
comparison, although natural hydrogels are more difficult to modify, they are more biocompatible; their 
natural state does not elicit the extreme inflammatory response that a synthetic polymer typically does. As 
biocompatibility is the most essential characteristic of components within this anti-inflammatory system, 
a natural hydrogel was selected for the design. Within the realm of natural hydrogels, there is a wide 
range of options. Polymers such as collagen are found naturally in the human body whereas chitosan, 
alginate, and other natural hydrogels are taken from other organisms, such as plants and crustaceans.  Of 
these chitosan stands out as a non-toxic, biodegradable, non-immunogenic hydrogel that is a deacetylated 
form of chitin. It can be used in many different applications, such as viscous solutions, spray-dried 
powders, and nanoparticles, depending upon the exact needs of the project. A viscous solution of chitosan 
gel would be the most optimal in this case at it creates a natural hydrogel that can be applied to a 
biosensor while also housing anti-inflammatory drugs or drug-releasing nanoparticles. This application 
has been utilized in previous studies, demonstrating that the hydrogel coating will not impede the 
sensitivity of the biosensor. (Muzzarelli, 2000) 
4.4 PLGA Nanoparticles 
Poly (lactic go-glycolic acid) (PLGA) is a common synthetic hydrogel widely used in drug-delivery 
application. It has been proven to be biodegradable, biocompatible, and modifiable, making it very 
attractive for use in delivering anti-inflammatory drugs to the site of a biosensor implantation. Many other 
hydrogels have been utilized to make nanoparticles, such as alginate, poly(vinyl alcohol) (PVA) and 
poly(ethylene oxide) (PEO). Each of these nanoparticles differs in size, degradation time, and various 
mechanical properties. (Hamidi, 2008) PLGA has the benefit of degrading into biocompatible 
compounds, lactic acid and glycolic acid, which are non-toxic to the human body. During the formation 
of these nanoparticles, the ratio of lactic acid and glycolic acid as well as the molecular weight dictates 
the degradation rate, allowing the particles to remain present and deliver drugs anywhere from weeks to 
years. For this project a degradation time of a few weeks was desired in order to avoid potential toxicity, 
and to be able to quantify the release profile in the limited amount of testing time (Danhier, 2012) A 
PLGA nanoparticle concentration of 12.5mg/mL was therefore selected to be imbedded in the chitosan 
hydrogel and increase the viability of the anti-inflammatory system. 
4.5 Anti-Inflammatory System 
In order to create an anti-inflammatory system that would prevent the development of fibrotic scarring 
and extend the functional life of a biosensor beyond the current 3 to 7 days the TiO2 nanotubes are to be 
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used in conjunction with 1% chitosan hydrogel, and PLGA nanoparticles. Ultimately, the biosensor itself 
would be made of Ti and anodized to create TiO2 nanotubes. This biosensor would then be dip-coated 
with PLGA nanoparticle-loaded chitosan hydrogel, as illustrated in Fig. 3.  
 
Figure 3: Schematic of complete anti-inflammatory system 
The PLGA nanoparticles would be embedded with dexamethasone, providing a more general reduction in 
the inflammation in addition to the macrophage-targeting nanotubes and biocompatibility-increasing 
hydrogel. It was hypothesized hypothesis that this system could reduce inflammation by synergistically 
preventing macrophage activation and reducing the overall cell response to the presence of a foreign 
body, subsequently preventing fibrotic scarring and increasing biosensor longevity. The following 
methods were utilized for the creation of the components of this system. 
5.0 Methodology 
In order to create this anti-inflammatory system for a subcutaneous biosensor, each component required 
creation and testing. Those components are the TiO2 nanotubes, the chitosan hydrogel, and the anti-
inflammatory drug-loaded PLGA nanoparticles. After these components are created and tested, they can 
be combined to create the final system. 
5.1 Titanium Nanotubes 
TiO2 nanotubes are formed by anodizing Ti foil, the depiction of which can be found in Fig. 4. In this 
study, Ti foil (99% pure, 0.127mm thick) was cut into 3x5 cm pieces and ultrasonically cleaned in 100% 
isopropanol for 15 minutes. Samples were anodized at 15V in 0.25M hydrofluoric acid for 45 minutes 
and subsequently annealed in a tube furnace at 400°C for 4 hours. After annealing, Ti samples were 
rinsed with DI water, pure isopropanol, and ultrasonically cleaned in pure isopropanol for 15 minutes. 
Scanning electron microscopy (SEM) imaging was used to characterize the annealed samples. The 
complete list of materials and protocol for this procedure can be found in Appendix A.  
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A    B  
Figure 4: (A) Depiction of anodizing system with Platinum mesh anode and Ti foil cathode, (B) Schematic nanotube 
formation during anodization (Brammer, 2011) 
In order to determine the size of the nanotubes, ImageJ software was utilized. The Image J measuring 
tools were calibrated and scaled to match the 400nm scale bar on the SEM images obtained during earlier 
characterization. Examples of these SEM images can be found below in Fig. 5. The inner and outer 
diameters of the tubes were measured , with the diameters were taken from the widest and narrowest 
sections and then averaged together. Approximately 70 nanotubes, which accounted for over 80% of the 
tubes on each image and roughly 134 values, were measured and averaged in order to get a proper 
representation of the tubes imaged. The data from this analysis is included in Appendix B. Prior to all in 
vitro testing TiO2 samples were cut into 0.5x0.5 cm squares and ultrasonically cleaned in pure ethanol in 
order to ensure sterility. 
 
A         B  
5.2 1% Chitosan Gel 
Chitosan from Sigma (from shrimp shells, ≥75% deacetylated) was dissolved in 2% acetic acid solution 
by magnetic stirring for 2 hours. The gel was then stored at room temperature until testing. For further 
information refer to the complete protocol in Appendix C. TiO2 and Ti samples were dipped in the gel 
prior to in vitro testing, and placed into individual wells in a 48-well plate. The coated samples in coated 
samples were then refrigerated at 4°C for 24 hours to dry, and then placed in a 37°C oven until testing. 
Figure 5: (A) Side view of annealed TiO2 Nanotubes, (B)Top-down cross section of annealed TiO2 Nanotubes  
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This final step was performed to ensure that the dried gel would not change in consistency when 
introduced to incubation temperatures. As no change was observed in the gel when transferred from the 
refrigerator to the oven, no further testing was performed on the chi-coated samples prior to cell seeding.  
5.3 PLGA Nanoparticles 
PLGA nanoparticles have the ability to maintain a sustained drug release profile for an average of 2 
weeks. For this delivery system, the anti-inflammatory drug dexamethasone would be utilized. However, 
in order to allow for ease of testing, FITC was used as it has a comparable molecular weight to 
dexamethasone, 389.38 g/mol versus 392.46 g/mol  respectively. FITC has fluorescence which will 
enable the release to be very easily quantified. The FITC was therefore loaded into the PLGA 
nanoparticles in the following procedure.  
5.3.1 Nanoparticle Fabrication 
In order to create the PLGA nanoparticles, a 5050 DLG mPEG 5000 (PLGA-PEG) was obtained from 
Evonik Corporation and utilized. These nanoparticles were created by dissolving 50 mg of the PLGA-
PEG mixture with 1 mg of FITC into a round bottom flask containing 400 μL of dichloromethane and 100 
μL of acetone. After the powders had completely dissolved, 2.5 mL of 4% polyvinyl alcohol (PVA) was 
added. This mixture was then sonicated for 3 minutes at a strength of 20W while being kept on ice. After 
sonification, the solution was rotor-evaporated until there had been a complete evaporation of the organic 
solvents. The remaining solute was resuspended in 3mL of ultrapure water. This suspension was then 
ultracentrifuged at 40,000 rpm for 45 minutes. The resulting precipitated nanoparticle pellet was then 
washed three times with ultrapure water. The pellet was resuspended in 3mL of ultrapure water and 
underwent mild sonication. This was centrifuged at 3,000 rpm for 5 minutes in order to remove any large 
aggregates. The solution was then flash-frozen on dry ice and lyophilized. In order to use the particles in 
further testing, they were resuspended in ultrapure water. The protocol for this process is included in 
Appendix D. The nanoparticle size was determined using Dynamic Light Scattering (DLS). As seen in 
Fig. 6, the nanoparticles had an average diameter of 170 nm.  
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Figure 6: DLS Graph displaying average diameter of FITC loaded PLGA nanoparticles 
5.3.2 FITC Release Study 
A standard curve for Fluorescein isothiocyanate (FITC) was prepared using concentrations of 0.5 μg/mL 
to 350 μg/mL FITC in PBS.  
To begin the study, the nanoparticles were re-suspended in PBS to create a 25 mg/mL solution. This 
solution was then mixed in a 1:1 ration with warm, liquid 2% agarose gel to create a 12.5 mg/mL 
nanoparticle solution which yields a 2% FITC concentration. Three capped, glass vials (vials 1-3) were 
filled with 100 μL of this agarose/nanoparticle solution and refrigerated to solidify the solution. Another 
three vials (vials A-C) were each filled with 150 μL of the solution and also refrigerated. After the gel had 
fully solidified (about 10 minutes after refrigeration), PBS was added to each vial, 250 μL in vials 1-3, 
and 300 μL in vials A-C. The vials were left for 24 hours in 37°C to simulate in vivo conditions. After 24 
hours, the PBS from each vial was collected and put into separate vials, then frozen. The PBS was 
replaced in each vial to equal the amount taken out. This process was repeated with time points at 1, 2, 3, 
5, 7, 9, 11, and 13 days. A protocol of this process is included in Appendix E. At the end of harvesting, 
the concentrations were analyzed with a Thermo Scientific Nanodrop 2000 Spectrophotometer in order to 
find the absorbance of the FITC to be compared to the standard curve. 
5.4 In Vitro Testing: Macrophage Viability, Adhesion and Activation 
The adhesion and activation properties of macrophages dictate the body’s immune response to a foreign 
material. As macrophage activation produces a different morphology than that of an inactivated cell, as 
seen in Fig. 7, qualitative data generated through images of the cells adherence to the different samples 
can indicate the intensity of the immune response. The samples to be tested for activation were an 
unmodified Ti foil control, TIO2 nanotubes, chitosan-coated Ti foil, and chitosan-coated TIO2 nanotubes.  
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Figure 7: SEM Image of inactivated (left) and activated (right) macrophages on chitosan-covered TiO2 nanotubes 
5.4.1 Macrophage-like Cells 
Immortalized macrophage cells, which consisted of macrophages harvested from C57bl/6 mice and 
treated with J2 virus in order to enable proliferation, were obtained as a gift from University of 
Massachusetts (UMASS) Medical School in order to gather preliminary adhesion and viability data. A 
media mixture of DMEM, 10% FCS, HEPES (11 ml of 1M per 500 ml bottle), and Cipro was used 
throughout for these immortalized macrophages. 10,000 cells were seeded per well, with each column of 
the well plate containing Ti foil controls, TIO2 nanotubes, chitosan-coated Ti foil, or chitosan-coated TIO2 
nanotubes; a schematic of this procedure can be found below in Fig. 8. 
         A           B          C          D            E          F 
  
Figure 8: Schematic of 48-well plate containing (A) media control, (B) Ti foil control, (C) TiO2 nanotubes, (D) Chitosan, 
(E) Chitosan-coated Ti foil , and (F) Chitosan-coated TiO2 nanotubes  
Two well plates containing identical substrates were utilized; one was allowed to proliferate for 24 hours 
and the other for 7 days. These durations were chosen because of their correspondence to the 
inflammatory response: 24 hours is the period during which initial macrophage activity would occur, and 
7 days is the desired period of time to extend biosensor functionality. Due to the ability of the 
immortalized macrophages to proliferate accurate viability, adhesion, and activation data were difficult to 
obtain. Therefore all initial testing using these cells was performed solely to validate experimental 
concepts and testing procedures.  
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5.4.2 Macrophages 
To rectify the problem of macrophage proliferation,  primary macrophages from C57 Black /6J 
(C57BL/6J) mice were obtained as a gift from UMASS Medical School. The above procedures were 
duplicated using this cell line, substituting the previous media for DMEM supplemented with 10% Fetal 
Bovine Serum and 1% Penicillin/Streptomycin. Following either 24 hours or 7 days, depending on the 
well plate, substrate samples were stained to determine macrophage viability and adhesion, and imaged to 
determine macrophage activation. 
5.4.2.1 Hoechst and Phalloidin Staining 
To determine macrophage viability and adhesion, a Hoechst and a Phalloidin stain were used on half of 
the samples in each well plate. The Phalloidin, which stains the F-actin filaments green, was prepared by 
mixing 5 μL of stock Phalloidin with 200 μL of PBS TWEEN, resulting in a dilute solution. The Hoechst 
stain, which stains cell nuclei blue, was prepared by mixing 1 μL of stock Hoechst with 1000 μL of PBS 
TWEEN, resulting in a usable dilute solution. To begin the study, the cells were washed twice with 10% 
PBS, and then fixed in 2% formaldehyde for 60 minutes. The wells were then washed three times with 
PBS. After aspirating the PBS, 2% BSA blocking agent was added to each sample and left for 5 minutes 
before being aspirated out. The dilute Phalloidin solution was added to each sample and left for 15 
minutes, making sure the sample was submerged. After, the Phalloidin solution was aspirated out and the 
dilute Hoechst solution was added to each well, enough to cover the sample, and left for 5 minutes. The 
stain solution was then aspirated out of the wells and replaced by 10% PBS, then stored in the 4°C fridge 
until imaging. A protocol of this procedure can be found in Appendix F. The samples were kept out of 
light by being wrapped in aluminum foil upon storage. A Leica Fluorescent Microscope system with 
image analysis software was used to image and record the samples. 
5.4.2.2 SEM Imaging 
SEM was utilized to qualitatively assess the adhesion and activation of the macrophages. The remaining 
half of the Ti and TiO2 samples in each well plate, those not used in staining, were imaged obtain these 
data. In order to prepare the samples for imaging, the cells first had to be fixed. This was done by adding 
approximately 4 μL of 2.5% gluteraldehyde to each media-filled well. After 10 minutes, the 
gluteraldehyde and media was aspirated out and another 5 μL of 2.5% gluteraldehyde was added to each 
well, ensuring the sample was covered. The sample was left in the gluteraldehyde for 15 minutes, and 
then the solution was aspirated out. A series of alcohol washes was then performed. First, 10% alcohol 
was added dropwise to each well until the sample was covered (approximately 5 drops) and then left for 
10 minutes. The alcohol was then aspirated out and this procedure was repeated using 30%, 50%, 70%, 
85%, 95%, and 100% ethanol. The samples were not allowed to dry out, so well by well, the ethanol was 
aspirated and immediately the higher concentration was added. After the 100% ethanol, each well was 
washed once more with the 100% ethanol. The cell fixation protocol can be found in Appendix G. The 
samples were then point-dried using an AutoSamdri-815 critical point dryer at UMASS Medical School. 
After all of the samples had been point dried, they were sputter-coated with 12 nm of gold/palladium 
alloy in a Cressington 208HR sputter coater at UMASS Medical School. An FEI Quanta 200 MKII FEG 
ESEM machine at UMASS Medical School equipped with an Oxford-Link EDS system was used to 
examine the sputtered samples. Images were taken of each of the samples for further analysis. 
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6.0 Results 
Through the aforementioned methodology, qualitative data demonstrating a validation of design concepts 
and design ability to reduce macrophage activity were obtained. Results on TiO2 nanotubes 
characterization and PLGA nanoparticle release were obtained separately from in vitro testing, which 
constituted the primary area of interest.    
6.1 Titania Nanotubes 
The TiO2 nanotubes were imaged using SEM at Northeastern University. These images were then 
analyzed using ImageJ to determine the average inner and outer diameters of the tubes. It was determined 
that the average inner diameter of the nanotubes was 42.3 nm and the average outer diameter was 63.8 
nm. This was slightly less than the suggested diameter of 70 nm. These tubes were also found to have an 
approximate length of 200 nm. SEM images of the TiO2 nanotubes following in vitro were also taken, and 
will be discussed in Section 6.3.2. 
6.2 FITC Release Study 
The FITC release study from the PLGA nanoparticles lasted the full 13 days of the study. The collected 
supernatant had been stored in the fridge until all sampled had been collected. Using a Thermo Scientific 
Nanodrop 2000 Spectrophotometer, the absorbance of solutions was analyzed in Alexa Fluor 488 and 
taken in triplicate. Each day’s readings were averaged together to get the mean and the standard deviation. 
These absorbance values were matched against the standard curve seen in Fig. 9. The equation of the 
linear-fit line was utilized in order to find the experimental FITC concentrations based upon the 
absorbance readings. 
 
Figure 9: Standard curve of FITC absorbance vs. concentration with a slope of 1.7162 and a fit of 0.9994 
Once the average absorbance was converted into average concentrations for each time point, they were 
plotted versus time in order to get the cumulative release curve found in Fig. 10. This was done for both 
the low volume wells of 100 μL of the 12.5 mg/mL nanoparticle/PBS solution and the high volume wells 
of 150 μL of the 12.5 mg/mL solution. 
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Figure 10: Cumulative concentration of FITC release from high volume and low volume wells demonstrating similar 
release profiles over the course of two weeks 
The resulting curves had an initial burst for the first 48 hours, after which it began to level. From day 5 
until the end of testing at day 13, the release remained quite constant at a concentration of 10 μg/mL.  
6.3 In Vitro Testing: 
The in vitro testing conducted on Ti foil, TiO2 nanotubes, chitosan-coated Ti foil, and chitosan-coated 
TiO2 nanotubes allowed the group to truly qualify the system design and determine if it was viable for 
future applications. The primary macrophages were utilized over the immortalized macrophages during 
this testing in order to gain an accurate assessment of cell viability without factoring in cell proliferation.  
During testing substrates were analyzed for macrophage viability, adhesion, and activation through 
Hoechst and Phalloidin staining and through SEM imaging. 
6.3.1 Hoechst and Phalloidin Staining 
Images of each sample were taken at the area of highest macrophage confluence, and both the green 
Phalloidin staining of the cell actin and blue Hoechst staining of the cell nuclei were apparent. Ti foil 
demonstrated higher rates of macrophage adhesion after 24 hours; however from observations of the 
location of cell action seen in Fig. 11 there did not appear to be any activation.   
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A   B  
C   D  
Figure 11: Fluorescence imaging of (A) Ti foil, (B) TiO2 nanotubes, (C) Chitosan-covered Ti foil, and (D) Chitosan-
covered ) TiO2 nanotubes after 24 hrs. Green Phalloidin is staining cell actin and blue Hoechst is staining cell nuclei 
Both Ti foil and chitosan-covered Ti foil had increased amounts of macrophage adhesion and activation 
after 7 days in comparison to the TiO2 and chitosan-coated TiO2 nanotubes.  TiO2 and chitosan-coated 
TiO2 nanotubes possessed equal amounts of cellular adhesion; however the macrophages on the chitosan-
coated samples were less activated than on those without the hydrogel as evidenced by the Phalloidin 
stain in Fig. 12.  
 A   B  
C   D  
Figure 12: Fluorescence imaging of (A) Ti foil, (B) TiO2 nanotubes, (C) Chitosan-covered Ti foil, and (D) Chitosan-
covered TiO2 nanotubes after 7 days. Green Phalloidin is staining cell actin and blue Hoechst is staining cell nuclei 
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6.3.2 SEM Imaging 
All samples demonstrated an amount of macrophage adhesion and activation, which was determined by 
cell morphology as discussed in Section 5.4. Ti foil possessed the highest amount of adhesion and 
activation among the 24 hours samples; chitosan-coated samples possessed the least with nearly all of the 
adhered macrophages remaining inactivated. Fig. 13 below depicts differences in macrophage adhesion 
and activation between the four sample types after 24 hours.  
 
A    B  
C  D  
Figure 13: SEM images of (A) Ti foil, (B) TiO2 nanotubes, (C) Chitosan-covered Ti foil, and (D) Chitosan-covered TiO2  
nanotubes 24 hrs after macrophage seeding. Green arrows indicate inactivated macrophages, red arrows indicated 
activated macrophages. 
 After 7 days both the Ti foil and TiO2 chitosan-coated samples demonstrated minimal adhesion and 
activation in comparison to the non-chitosan coated samples. SEM images of these samples are seen in Fig. 
14. Areas where the chitosan layer had torn were more attractive to macrophage adhesion, as can be 
observed in in part C of Fig. 14.  
 
 
 
 
20 
 
A  B  
C  D  
Figure 14: SEM images of (A) Ti foil, (B) TiO2 nanotubes, (C) Chitosan-covered Ti foil, and (D) Chitosan-covered TiO2 
nanotubes 7 days after macrophage seeding. Green arrows indicate inactivated macrophages, red arrows indicated 
activated macrophages. Note the torn chitosan on (C), and the macrophage adherence and activation to the exposed Ti 
foil 
This unexplained occurrence was observed only on Ti foil samples, with four of the imaged chitosan-
coated Ti foil samples displaying torn chitosan in the center of the substrate. Additional depictions of 
these chitosan tears are shown in Fig. 15. TiO2 samples only exhibited this disturbance on the corners 
where they had been handled by forceps prior to imaging. 
 
Figure 15: Examples of chitosan tears on chitosan-coated Ti foil samples 
Further images in Fig. 16 show how the macrophages adhere to the TiO2 nanotubes. These show the areas 
in which the filopodia actually adhered in the more activated macrophages. This also helps to show the 
state of the TiO2 nanotubes after testing has been performed.  
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Figure 16: SEM images of macrophage adherence to TiO2 nanotubes 
In Fig. 16, there are also sections in which disturbances in the TiO2 nanotubes are seen. This is further 
illustrated in Fig. 17, where the sectioning off and breaks in the TiO2 nanotube shelves are clearly visible 
in contrast to the titanium beneath. These areas can be seen on most of the uncoated TiO2 samples from 
both the Day 1 and Day 7 samples. 
 
Figure 17: SEM image deterioration of TiO2 nanotubes taken following testing 
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7.0 Analysis and Discussion 
Through the results found in Chapter 6, an analysis was conducted to find patterns in observations and 
identify unexpected occurrences in the experimental testing. These observations have helped to form 
further hypotheses and decisions for continuations in testing, allowing for future recommendations to be 
formulated. 
7.1 Analysis of Experimental Testing 
Experimental testing allowed provided the data necessary for the design validation and the following 
analysis of these data expands upon the implications of these results. This is especially true for qualitative 
images taken using fluorescence imaging and SEM. 
7.1.1 Titania Nanotubes 
The TiO2 nanotubes were a central part to the project and had some interesting results. The formulation of 
the nanotubes, though done properly, may not have been the correct diameter. This is due to the fact that 
the literature simply stated that the nanotubes should have a diameter of 70 nm in order to reduce 
macrophage activation. This is very general as the nanotubes have an inner and an outer diameter with 
varying shell thicknesses. The created nanotubes still did seem to reduce the macrophage adhesion and 
activation, as seen in Fig. 13 and Fig. 14, in comparison to the plain titanium foil. However, there were 
still instances of the macrophages activating on the TiO2 nanotubes, as clearly seen in Fig. 16. This may 
have been in sections where the average diameter of the nanotubes was either significantly greater or less 
than the recommended 70 nm.  
The sectioning off of the TiO2 nanotubes seen in Fig. 17 was an unexpected observation on the uncoated 
samples. This may be linked to the handling of the samples during the fixation process.  This was not seen 
in any of the chitosan-coated samples, though this is probably due to the lack of visibility through the 
hydrogel. The reason behind the nanotube failure should be further investigated, especially as the 
attachment of the chitosan hydrogel may be incredibly dependent upon it. Losing TiO2 nanotubes also 
brings the problem of having loose particles in the body, which has the high potential for creating a 
further immune response. This can be extremely detrimental to the anti-inflammatory system and 
therefore must be avoided. It can be assumed that this would not be very great of a problem so long as the 
nanotubes are coated in a hydrogel which would effectively prevent the nanotubes from becoming loose 
within the body, however it would be best to conduct further testing first to ensure there is no way for this 
to happen. The final product also probably would not have this problem is it is unique to the foil being 
bent during testing, however the stresses placed upon the actual biosensor would have to be analyzed to 
make sure there is no similar occurrence. 
7.1.2 FITC Release Study 
The FITC release from the PLGA nanoparticles successfully demonstrated the ability for the 
nanoparticles to release a molecule of a molecular weight of 389.38 g/mol for a duration of two weeks. In 
the final design of the anti-inflammatory system, dexamethasone will be loaded into the nanoparticles in 
place of FITC. Dexamethasone will also need to be tested for release but expected results should be very 
similar as its molecular weight is 392.46 g/mol, almost identical to that of FITC. As the molecular 
weights are marginally different there slight modifications to the amount of dexamethasone loaded into 
the nanoparticles may have to be made. However, there is no reason to suspect that large alterations will 
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be necessary. There may also be some further discrepancies on the size of the nanoparticles as they alter 
batch to batch. Different sizes may be tested in future studies depending upon the abilities of future labs. 
This release study will also need to be performed with 1% chitosan hydrogel instead of 2% agarose gel, in 
order to more properly quantify the release in future testing. Once these alterations have been tested, 
preliminary in vivo testing may be able to begin. 
7.1. 3 Macrophage Adhesion and Activation 
From the fluorescence and SEM imaging it was clearly demonstrated that the chitosan-covered TiO2 
nanotubes possessed the least amount of macrophage activation after both 24 hours and 7 days. These 
qualitative data are critical as they validate the design concept that the combination of TiO2 nanotubes and 
1% chitosan hydrogel would have an inhibitory effect on macrophage activity, and thus the subsequent 
recruitment of other cells to the biosensor and the eventual development of fibrotic scarring.  
The effect of the chitosan hydrogel on macrophage behavior was also apparent, as all chitosan-covered 
samples demonstrated reduced macrophage adhesion and activation in comparison with their non-
chitosan counterparts. The discrepancy between the two sample types, chitosan-covered and non-chitosan 
is most clearly evident in the day 7 samples in Fig. 14, evidencing the ability of chitosan to have an anti-
inflammatory effect for the desired duration of time.  
The critical difference in macrophage activity on chitosan-covered Ti foil and chitosan-covered TiO2 
nanotubes was the tearing of the hydrogel on the former. Multiple samples of chitosan-covered Ti foil 
possessed disturbances in the hydrogel layer, as depicted in Figs. 14 and 15. Macrophages gravitated 
towards the areas where these disturbances had occurred, adhered to and activation on the exposed foil.  
The reason for this discrepancy has not been determined, and suggestions for future analysis and testing 
are discussed in Section 7.2 below.  
7.2 Future Recommendations 
The anti-inflammatory system design of this project demonstrated potential for use in subcutaneous 
biosensor applications based upon its ability to reduce macrophage activity and maintain an extended 
release profile, but further work is needed to ensure its success. Initial considerations include alterations 
to the testing parameters. In terms of the nanoparticle release study, it is recommended that the test is 
performed with the hydrogel selected for the specific design, 1% chitosan, rather than 2% agarose. Prior 
to in vivo testing, dexamethasone must be loaded into the nanoparticles and a release study performed on 
them. A release study to failure should also be conducted to determine the full potential of the 
nanoparticles.  
After the testing has moved in vivo to initial mouse testing, further areas for improvement can be 
suggested. The 1% chitosan hydrogel should be characterized, preferably utilizing an AFM, in order to 
determine the mechanical properties and adhesion of the chitosan when it has been dried on the TiO2 
nanotubes. In order to undergo insertion, the chitosan hydrogel will need to be analyzed for shear stress 
when attached to the TiO2 nanotube-biosensor, and possibly modified to ensure that the hydrogel will stay 
intact. A more effective means of applying the chitosan in an even and fully-coating manner should be 
investigated.  
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Throughout the course of this study, additional questions were raised on the adherence of the chitosan 
hydrogel to the Ti Foil in comparison to its adherence to the TiO2 nanotubes; however, due to time 
limitations it was not possible to investigate this issue further. For future studies, the tears in the chitosan 
hydrogel that appeared on the Ti foil should be further examined. It is hypothesized that the TiO2 
nanotubes help the chitosan to adhere more properly as the chitosan is able to slightly enter the tubes, thus 
providing better anchorage to the surface, however additional testing should be performed to prove or 
disprove this hypothesis. Other surface modifications to the Ti can also be investigated to see the different 
possibilities of chitosan adhesion. These additional surface modification considerations may be essential 
if future testing of a TiO2 nanotube biosensor reveals weakened sensing capabilities. 
Further items for investigation include the damage to the TiO2 nanotubes observed in the Fig. 17. Even 
though this occurrence might only be found on the foil and will not be observed on the actual biosensor, it 
should still be tested to ensure that the hydrogel adheres properly and the nanotubes do not become loose 
within the body. Additional observations on the TiO2 nanotubes were made during testing and could be 
investigated further; however, they are not discussed outside of Appendix H as they were not excessively 
pertinent to this project. 
This possible occurrence of altered biosensor sensitivity should be investigated in addition to all of the 
aforementioned recommendations. It is recommended that the metabolic biosensor be made of titanium 
and then anodized as by the protocol in Appendix A to form TiO2 nanotubes on the surface of the sensor. 
The sensor must then be tested, without any sort of coating, in vitro and in vivo to ensure functionality. 
After the sensor has been proven to work effectively and efficiently, further testing with hydrogel and 
drug-release systems can be performed to find the optimal coating layer so as to retain high performance 
abilities of the biosensor. When the system is fully completed and all components have been tested, more 
extensive in vivo studies can begin. During in vivo studies, the entire inflammatory system can then be 
analyzed as opposed to just the macrophages. It would be beneficial to then conduct macrophage 
activation testing using cytokine levels as opposed to the visual observations used in this project. It is the 
hope that after this testing has been done, this anti-inflammatory system may be able to be adopted into 
wide-spread use, thus completing the objectives. 
8.0 Conclusion 
To summarize, the first-generation MQP design of TiO2 nanotubes, 1% chitosan hydrogel, and PLGA 
nanoparticles qualitatively demonstrated an ability to reduce macrophage adhesion, inhibit macrophage 
activation, and maintain a release profile of pharmaceutical compounds for two weeks. Although there are 
areas to be considered for additional testing, as discussed above in Section 7.2, the data presented above 
suggest that this anti-inflammatory design has a strong potential for use as a subcutaneous biosensor that 
generates a reduced inflammatory response and delays the development of fibrotic scarring by inhibiting 
macrophage activity, ultimately extending the functional lifetime of the device.  
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Appendices 
Appendix A: Anodization of Titanium Foil 
Adapted from:  Eugen Panaitescu of the Northeastern University Department of Physics  
 
Materials 
 0.127mm annealed 99% Ti foil 
 DI 
 Isopropanol  
 0.25M Hydrofluoric Acid  
 
 
Procedure 
Titanium Foil Preparation  
1. Cut foil into 3x4 cm 
a. One 4x4 cm sample and two 3x4 cm samples 
2. Press cut samples to flatten 
a. Using Carver Laboratory Press 
b. Only did one sample (left unwanted divots) 
3. Ultrasonically clean in isopropanol for 15 mins  
4. Air dry with pressurized hose 
5. Rinse with DI 
6. Air dry with pressurized hose 
 
Anodization 
1. Anodize Ti sample for 45 mins at 15 V 
a. In 0.25M HF 
b. Distance between cathode and anode was 5 cm 
2. Rinse completed sample in DI 
3. Rinse in isopropanol 
4. Ultrasonically clean in isopropanol for 15 mins 
 
Notes: 
 Have samples as flat as possible so distance between cathode and anode is equal 
 Be consistent with distance between cathode and anode 
 Do not have Ti foil sit in HF before voltage is applied 
o Oxidation will occur  
 Sterilize samples before cell use 
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Appendix B: Image J Data 
For both the inner and outer diameters, the average cross-section was taken. For each of the odd 
numbered diameters, the largest diameter was taken from an individual tube, with the even numbered 
diameters being the smallest diameter from the same tube. This allows for the average diameter of all the 
tubes to have been taken. This was necessary due to the differences in cross-sectional shape. 
Inner 
Diameter Length (nm) 
Outer 
Diameter 
Length 
(nm) 
1 35.373  1 67.303 
2 32.093  2 63.264 
3 40.823  3 65.825 
4 30.388  4 73.919 
5 44.012  5 74.011 
6 37.474  6 60.686 
7 51.479  7 51.346 
8 47.705  8 59.595 
9 45.955  9 69.5 
10 30.478  10 53.304 
11 52.53  11 58.415 
12 30.478  12 47.36 
13 41.717  13 71.534 
14 30.343  14 62.044 
15 52.996  15 74.837 
16 41.848  16 63.156 
17 53.227  17 66.486 
18 46.31  18 52.918 
19 46.575  19 57.377 
20 37.401  20 51.052 
21 42.335  21 69.046 
22 44.012  22 50.703 
23 48.809  23 56.295 
24 41.421  24 51.266 
25 51.664  25 63.609 
26 41.421  26 60.528 
27 45.717  27 77.808 
28 28.148  28 48.949 
29 49.614  29 72.67 
30 37.764  30 57.066 
31 33.469  31 68.749 
32 26.135  32 58.438 
33 44.012  33 66.63 
34 19.903  34 64.377 
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35 40.89  35 62.94 
36 41.322  36 67.465 
37 60.776  37 72.614 
38 40.924  38 49.971 
39 55.93  39 76.48 
40 36.7  40 58.996 
41 53.227  41 71.381 
42 43.638  42 51.638 
43 49.724  43 72.802 
44 44.105  44 59.066 
45 38.052  45 76.104 
46 43.386  46 63.802 
47 56.125  47 61.157 
48 38.16  48 49.531 
49 48.19  49 69.066 
50 31.794  50 51.743 
51 48.613  51 66.63 
52 41.717  52 70.669 
53 31.794  53 73.195 
54 25.819  54 61.246 
55 31.405  55 77.421 
56 31.405  56 65.804 
57 31.361  57 76.694 
58 31.578  58 74.837 
59 44.475  59 66.053 
60 38.052  60 57.827 
61 52.269  61 69.046 
62 42.141  62 65.825 
63 38.339  63 83.923 
64 40.521  64 60.528 
65 49.144  65 69.441 
66 36.401  66 68.749 
67 47.36  67 54.645 
68 34.075  68 66.63 
69 61.179  69 74.011 
70 38.052  70 41.618 
71 53.355  71 78.941 
72 41.454  72 60.641 
73 65.493  73 72.444 
74 34.868  74 62.307 
75 62.57  75 72.896 
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76 31.923  76 70.611 
77 36.7  77 56.222 
78 29.935  78 43.007 
79 62.11  79 58.039 
80 34.035  80 50.46 
81 43.481  81 62.809 
82 30.478  82 58.227 
83 36.514  83 74.545 
84 36.401  84 52.918 
85 48.19  85 73.027 
86 28.148  86 48.949 
87 41.421  87 62.044 
88 32.6  88 53.304 
89 50.569  89 61.955 
90 41.355  90 62.831 
91 49.587  91 56.802 
92 44.903  92 61.335 
93 54.945  93 68.749 
94 46.104  94 52.529 
95 45.717  95 77.843 
96 26.907  96 48.387 
97 65.805  97 59.71 
98 45.925  98 60.324 
99 55.168  99 70.669 
100 43.638  100 58.996 
101 58.439  101 81.395 
102 50.026  102 55.019 
103 52.996  103 67.949 
104 46.399  104 66.301 
105 28.148  105 71.762 
106 26.652  106 56.489 
107 51.664  107 82.063 
108 33.099  108 51.77 
109 56.803  109 66.136 
110 29.798  110 67.768 
111 40.89  111 90.29 
112 28.533  112 59.595 
113 41.355  113 78.316 
114 36.364  114 56.994 
115 47.591  115 60.098 
116 34.75  116 47.273 
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117 44.964  117 71.093 
118 34.075  118 47.962 
119 39.978  119 63.264 
120 39.184  120 65.492 
121 53.966  121 65.804 
122 39.428  122 51.346 
123 47.934  123 86.772 
124 29.429  124 62.831 
125 66.63  125 65.116 
126 22.052  126 70.165 
127 72.01  127 72.161 
128 25.66  128 65.388 
129 57.662  129 78.542 
130 42.367  130 57.945 
131 49.697  131 68.27 
132 30.162  132 52.918 
133 38.904  133 89.148 
134 47.705  134 44.505 
AVERAGE:  42.29765  135 66.301 
  
 136 56.295 
  
 137 50.703 
  
 138 73.176 
  
 AVERAGE: 63.80833 
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Appendix C: Fabrication of 1% Chitosan Gel 
Adapted from: (Zanzan 2008)   
 
Materials 
 Chitosan powder (from shrimp shells, ≥75% deacetylated) from Sigma  
 2% Acetic Acid  
 
 
Procedure 
1. Dissolve chitosan in 2% acetic acid  
2. Magnetic stir for 2 hrs at room temp (or until all powder has dissolved) 
3. Store at room temperature 
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Appendix D: Nanoparticle Fabrication 
Adapted from: (Chenna, 2011) performed by Dina Rassias: 
Materials 
 5050 DLG mPEG 5000 (PLGA-PEG) (Evonik Corporation) 
 Fluorescein 5(6)-isothiocyanate (FITC) (≥ 90% HPLC from Sigma) 
 Dichloromethane 
 Acetone 
 4% polyvinyl alcohol 
 DI water 
 
Procedure 
1. Dissolve 50mg of PLGA-PEG and 1mg of FITC in 400uL dichloromethane and 100uL acetone 
(8:2) in a round bottom flask 
2. Add 2.5 mL of 4% polyvinyl alcohol to the resulting solution 
3. Sonicate the solution for 3 mins at 20W , 4C 
4. Rotor-evaporate until complete evaporation of organic solvents. 
5. Re-suspend in 3mL of ultrapure water. 
6. Ultracentrifuge resulting suspension at 40,000 rpm for 45 mins 
7. Wash the precipitated nanoparticle pellet 3X with ultrapure water 
8. Re-suspend in ultrapure water (3ML), mild sonication 
9. Centrifuge at 3000 rpm for 5 mins to remove any large aggregates 
10. Flash freeze on dry ice and lyophilize 
11. Re-suspend in ultrapure water with amount for desired concentration   
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Appendix E: FITC Release Study Protocol 
Generated from: Suggestions by Prof. Jain of WPI 
Materials 
 Fluorescein 5(6)-isothiocyanate (FITC) (≥ 90% HPLC from Sigma) 
 Dimethyl sulfoxide (DMSO) (for molecular biology ≥99.9% from Sigma) 
 10% PBS 
 PLGA nanoparticles (Created by Dina Rassias) 
 2% agarose gel 
 
Procedure 
Standard Curve  
Note: Keep FITC out of light as much as possible 
1. Measure out 1μg of FITC with an equal amount of DMSO.  
2. Dilute FITC solution with PBS to get a concentration of 10 μg/mL. 
3. Dilute a portion of the 10 μg/mL with an equal amount of PBS to get a 5 μg/mL solution.  
4. Repeat Step 3 to get 2.5 μg/mL, 1.25 μg/mL, 0.625 μg/mL, 0.3125 μg/mL, 0.15625 μg/mL, 
0.078125 μg/mL, 0.039063 μg/mL, and 0.019531 μg/mL solutions. 
5. To test the absorbance of the FITC, mix each sample by pitetting. 
6. On the Nanodrop 2000 software, select BSA and Proteins, then AlexaFluor 488 for accurate 
readings.  
7. Wash Nanodrop with PBS prior to testing and use PBS to calibrate the system. 
8. Use Kim Wipe to remove PBS before adding 5 μL of lowest concentration, mixed FITC solution.  
9. Run the sample, wipe off drop after test, and re-test the same concentration twice more, 
successfully testing the concentration in triplicate. 
10. Wipe residual FITC drop from Nanodrop. Rinse with PBS, then re-zero with fresh PBS. 
11. Repeat steps 7-9 for each concentration, making sure to mix each solution prior to each run.  
12. Average the readings from Abs. 1 data for each concentration.  
13. Plot average Absorbance readings versus the concentration and find the linear equation. 
Release Study 
1. Resuspend PLGA nanoparticles in PBS to create 25 mg/mL solution 
2. Mix in a 1:1 ration with warm, liquid 2% agarose gel to create a 12.5 mg/mL nanoparticle 
solution (2% FITC concentration) 
3. Fill glass vials #1, #2, #3 with 100 μL of agarose/nanoparticle solution, fill vials A, B, C with 150 
μL of the solution. Cap and refrigerate vials at 4°C. 
4. Leave in 4°C until solidified (~10 minutes) 
5. Add 250 μL of 10% PBS to vials #1-3, add 300 μL in vials A-C.  
6. Recap vials and place in 37°C for 24 hrs to simulate in vivo conditions.  
7. Collect the PBS from each vial and place in separate, marked vials. Store in fridge at 4°C. 
8. Replace the amount of PBS harvested from each vial with fresh PBS and place back in 37°C 
incubator. 
9. Repeat steps 7-8 at time points 2, 3, 5, 7, 9, 11, and 13 days after initial PBS added to vials. 
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10. To test the absorbance of the FITC, mix each sample by pipetting. 
11. On the Nanodrop 2000 software, select Proteins & Labels, then Alexa Fluor 488 for Dye 1 for 
accurate readings.  
12. Wash Thermo Scientific Nanodrop 2000 Spectrophotometer with PBS prior to testing and use 
PBS to calibrate the system. 
13. Use Kim Wipe to remove PBS before adding 5 μL of the Day 1, Vial 1, mixed FITC solution.  
14. Run the sample, wipe off drop after test, and run Day 1, Vial 2. 
15. Run the sample, wipe off drop after test, and run Day 1, Vial 3. 
16. Wipe residual FITC drop from Nanodrop. Rinse with PBS, then re-zero with fresh PBS. 
17. Repeat steps 7-9 for each day in vials 1-3, making sure to mix each solution prior to each run.  
18. Repeat steps 14-19 with vials A-C. 
19. Average the readings from Dye 1 Abs data for each day and each well volume (100 μL and 150 
μL) and get the standard deviation. 
20. Utilize the linear equation of the standard curve to get the concentrations of each day and each 
well volume, as well as the standard deviation. 
21. Add concentrations to one another to get accumulation of the FITC over the days. 
22. Plot the concentrations of each well type versus the day to get the cumulative release of the FITC 
from each of the well types, as well as the error bars in accordance to the standard deviations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Appendix F: Hoechst and Phalloidin Staining 
Adapted from:  Yuan Yin and Professor Pins 
Materials 
 10% PBS 
 2% formaldehyde 
 2% BSA 
 Phalloidin 
 PBS TWEEN 
 Hoechst 
 
Procedure 
1. Aspirate media from wells, add in ~5 drops 10% PBS 
2. Aspirate PBS after 5 minutes, add ~5 drops 
3. Aspirate PBS after 5 minutes 
4. Fix cells with ~7 drops of 2% formaldehyde, ensure they are covered 
5. Leave for 60 minutes 
6. Aspirate out the formaldehyde 
7. Add ~5 drops PBS, leave for 5 min and aspirate 
8. Repeat step 7 twice more 
9. Add 200 μL of 2% BSA blocking agent to each sample (ensure it is covered) 
10. Aspirate blocking agent after 5 minutes 
11. Add freshly prepared Phalloidin stain (ensure sample is covered) 
a. Mix 5μL of stock Phalloidin stain with 200μL PBS TWEEN 
12. Leave Phalloidin stain in wells for 15 min, then aspirate 
13. Add freshly prepared Hoechst stain 
a. Mix 1μL of stock Hoechst stain with 1000μL PBS TWEEN 
14. Leave Hoechst stain in  wells for 5 min, then aspirate 
15. Add normal PBS to each well (ensure sample is covered) 
16. Cover well-plate with aluminum foil to block out light, store in 4°C fridge until imaging. 
17. Image cells with a Leica Fluorescent Microscope system with image analysis software  
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Appendix G: Cell Fixation for SEM Imaging 
Adapted from: Gregory Hendricks of UMASS Medical School 
Materials 
 2.5% gluteraldehyde 
 10%, 30%, 50%, 70%, 85%, 95%, 100% ethanol 
 Palladium/gold alloy 
 
Procedure 
1. For a 96 well plate, add 4 drops of 2.5% gluteraldehyde from a glass-pipette to each well to be 
fixed. Media should still be in the well. 
2. Wait 10 minutes, then aspirate media/gluteraldehyde. 
3. Add 5 drops gluteraldehyde to each well (ensure it covers the sample). Wait 15 minutes, then 
aspirate out.  
4. Begin ethanol washes by adding ~5 drops of 10% ethanol to each well (ensure sample is 
covered). 
5. After 10 minutes, aspirate and immediately add ~5 drops of 30% ethanol to each well separately 
(ensure the sample is never out of ethanol long enough to dry out.) 
6. Repeat step 5 with a series of 50%, 70%, 85%, 95%, and 100% ethanol. (be especially careful 
when using ethanol above 70% as it dries very quickly) 
7. Wash with 100% ethanol again and leave samples in 100% ethanol until point-drying. 
8. Place each sample into a “marshmallow” or other penetrable basket designed for the point-drier. 
Make sure basket is marked and the bottom side of the sample has been scratched to indicate 
what side has macrophages. Make sure each basket remains submerged in 100% ethanol and the 
transfer of the sample from the well-plate to the baskets is quick. 
9. Point-dry the samples in a AutoSamdri-815 critical point dryer. 
10. After drying, mount samples on metal stubs to load into the SEM machine. Use carbon tape to 
attach them, ensure the scratched, bottom side of the sample is down. Make sure samples are 
noted to be able to tell the different sample types. 
11. Load samples into a Cressington 208HR sputter coater. 
12. Sputter samples with 4nm of palladium/gold alloy. Repeat two times to get a total thickness of 
12nm of the alloy 
13. Load the samples into an FEI Quanta 200 MKII FEG ESEM machine equipped with an Oxford-
Link EDS system for imaging and analysis.  
14. Image each sample. 
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Appendix H: Titania Nanotube Discoloration  
In initial macrophage adhesion and activation studies, immortalized macrophages were seeded onto the 
four different sample types, including the TiO2 nanotube samples. It was on these nanotube samples that 
there was a discrepancy with the macrophage adhesion. Fig. 18 below shows the pattern of macrophage 
adhesion to the lighter colored areas of the nanotubes sample. 
 
Figure 18: Immortalized macrophages adhered to the light areas of TiO2 nanotubes on a Day 1 chitosan-coated TiO2 
nanotube sample. 
In the image above there are obvious streaks of light and dark areas, with the macrophages only adhering 
to the lighter areas. When the physical sample was analyzed out of the SEM, it appeared that the different 
colorations corresponded to the color-changes of the titania. Due to the anodization process, the titania 
turned from gray to luminescent pink on some areas of the sample. When conferring with Northeastern 
University about this difference, they stated that the difference in color should not translate to a different 
color in the SEM, nor should it have different properties from the gray titania. This was not an isolated 
occurrence as it was observed on other samples. Fig. 19 demonstrates the findings of an uncoated, TiO2 
nanotube sample seeded with primary macrophages at Day 1, where this occurrence is also present. It is 
clearly visible that there are fewer macrophages adhered to the darker area, and all of which are in their 
spherical, inactivated state. This is different in comparison to the light areas, where there is much greater 
macrophage adhesion as well as activation. 
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Figure 19: Light and dark areas of an uncoated TiO2 nanotube sample seeded with primary macrophages on Day 1. 
Notice the inactivated macrophages on the dark areas and the activated ones on the light. 
This continued on to Day 7 of the primary macrophage testing. Fig. 20 depicts macrophage avoidance of 
the darker area, and their activation solely in the lighter side of the partition.  
 
Figure 20: Day 7 primary macrophages on uncoated TiO2 nanotubes. 
This was an unexpected discovery, and one that was not explored further during the course of this project 
due to time constraints; future investigation into this subject is suggested. If the titanium can be anodized 
to have more of this darker area, inflammation may be further reduced as macrophage adhesion and 
activation is nearly eliminated. 
